Literature DB >> 17062641

Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.

Natsumi Yamamoto1, Gunay Mammadova, Robert X-D Song, Yasuo Fukami, Ken-ichi Sato.   

Abstract

Here we address the molecular mechanism of serum-independent survival and growth of human bladder carcinoma cell line 5637. Serum starvation promoted tyrosine phosphorylation of a 145-kDa protein and activation of the tyrosine kinase Src and the receptor for epidermal growth factor (EGFR) over a slow time course (>8 hours). The phosphorylated 145-kDa protein was identified as the beta-subunit of c-Met/hepatocyte growth factor (HGF) receptor, p145(met), in which tyrosine residues 1003, 1234, and 1235 were phosphorylated. Inhibitors of Src (PP2, SU6656) or EGFR (AG99), but not p145(met) (K252a), effectively blocked tyrosine phosphorylation of p145(met) and promoted cell death accompanied by activation of caspase-like proteases. Conditioned medium from the serum-starved 5637 cells or purified EGF readily promoted the activation of Src and EGFR, and tyrosine phosphorylation of p145(met) in normally grown 5637 cells, suggesting that autocrine signaling of EGFR ligands is responsible for signal transduction events in serum-starved cells. Consistent with this idea, a monoclonal antibody against EGFR that would interfere with the ligand binding to EGFR blocked tyrosine phosphorylation events and promoted the caspase activation and cell death in serum-free conditions. Such apoptotic cell death was also induced by pretreatment of cells with a high concentration of HGF that downregulated endogenous p145(met). Nevertheless, Cu2+ ions, competitive inhibitors for HGF-binding to p145(met), did not show any effect on cellular functions in serum-free conditions. These results suggest that the serum-independent growth of 5637 cells involves the transmembrane signaling cascade via EGFR ligand(s) (but not HGF), EGFR, Src and p145(met).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17062641     DOI: 10.1242/jcs.03236

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  32 in total

1.  Effect of EGF-receptor tyrosine kinase inhibitor on Rab5 function during endocytosis.

Authors:  Ivan Jozic; Samar C Saliba; M Alejandro Barbieri
Journal:  Arch Biochem Biophys       Date:  2012-06-05       Impact factor: 4.013

Review 2.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

3.  A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma.

Authors:  Craig W Menges; Yibai Chen; Brooke T Mossman; Jonathan Chernoff; Anthony T Yeung; Joseph R Testa
Journal:  Genes Cancer       Date:  2010-05-01

4.  Prediction of functional phosphorylation sites by incorporating evolutionary information.

Authors:  Shen Niu; Zhen Wang; Dongya Ge; Guoqing Zhang; Yixue Li
Journal:  Protein Cell       Date:  2012-07-16       Impact factor: 14.870

5.  Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53.

Authors:  Renyuan Zhou; Reneé Shanas; Mark A Nelson; Achyut Bhattacharyya; Jiaqi Shi
Journal:  Int J Cancer       Date:  2010-01-15       Impact factor: 7.396

6.  Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.

Authors:  Vernon T Phan; Xiumin Wu; Jason H Cheng; Rebecca X Sheng; Alicia S Chung; Guanglei Zhuang; Christopher Tran; Qinghua Song; Marcin Kowanetz; Amy Sambrone; Martha Tan; Y Gloria Meng; Erica L Jackson; Franklin V Peale; Melissa R Junttila; Napoleone Ferrara
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

7.  EGFR/Met association regulates EGFR TKI resistance in breast cancer.

Authors:  Kelly L Mueller; Zeng-Quan Yang; Ramsi Haddad; Stephen P Ethier; Julie L Boerner
Journal:  J Mol Signal       Date:  2010-07-12

8.  Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.

Authors:  Stuart Thomson; Filippo Petti; Izabela Sujka-Kwok; David Epstein; John D Haley
Journal:  Clin Exp Metastasis       Date:  2008-08-12       Impact factor: 5.150

9.  Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.

Authors:  Jeannine Garnett; Vaibhav Chumbalkar; Brian Vaillant; Anupama E Gururaj; Kristen S Hill; Khatri Latha; Jun Yao; Waldemar Priebe; Howard Colman; Lisa A Elferink; Oliver Bogler
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715

10.  Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer.

Authors:  Z Timsah; Z Ahmed; C Ivan; J Berrout; M Gagea; Y Zhou; G N A Pena; X Hu; C Vallien; C V Kingsley; Y Lu; J F Hancock; J Liu; A B Gladden; G B Mills; G Lopez-Berestein; M-C Hung; A K Sood; M Bogdanov; J E Ladbury
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.